Drug Search Results

Cyclobarbital

Alternative Names: cyclobarbital
Latest Update: 2023-05-10
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Germany | Ireland | Russia | Taiwan

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cyclobarbital

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success

Recent News Events

Date	Type	Title
05/10/2023	PubMed	New approach for barbiturates, phenytoin, methyprylon and glutethimide determination and fragmentation (UHPLC-MS/MS).
04/15/2023	PubMed	Therapeutic potentials of Adenostemma lavenia (L.) O.Kuntze evidenced into an array of pharmacological effects and ligand-receptor interactions.
02/01/2023	PubMed	Presence of potent inhibitors of bacterial biofilm associated proteins is the key to Citrus limon's antibiofilm activity against pathogenic Escherichia coli.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions